Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation

References

• Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N. Engl. J. Med.351(27), 2832–2838 (2004).
   PubMed Web of Science ®Google Scholar
• Redeker AG, Mosley JW, Gocke DJ, McKee AP, Pollack W. Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. N. Engl. J. Med.293(21), 1055–1059 (1975).
   PubMed Web of Science ®Google Scholar
• Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology32(6), 1189–1195 (2000).
   PubMed Web of Science ®Google Scholar
• Schilling R, Ijaz S, Davidoff M et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J. Virol.77(16), 8882–8892 (2003).
   PubMed Web of Science ®Google Scholar
• Wiseman E, Fraser MA, Holden S et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med. J. Aust.190(9), 489–492 (2009).
   PubMed Web of Science ®Google Scholar
• Gane E. Hepatitis B immunoglobulin immunoprophylaxis for hepatitis B: High, low, or no dose? Liver Transpl.16(S2), S36–S39 (2010).
   Google Scholar
• Mast EE, Margolis HS, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm. Rep.54(RR-16), 1–31 (2005).
   PubMedGoogle Scholar
• Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm. Rep.55(RR-16), 1–33; quiz CE1–4 (2006).
   PubMedGoogle Scholar
• Hann HW, Hann RS, Maddrey WC. Hepatitis B virus infection in 6,130 unvaccinated Korean-Americans surveyed between 1988 and 1990. Am. J. Gastroenterol.102(4), 767–772 (2007).
   PubMed Web of Science ®Google Scholar
• Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N. Engl. J. Med.294(14), 746–749 (1976).
   PubMed Web of Science ®Google Scholar
• Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ332(7537), 328–336 (2006).
   PubMed Web of Science ®Google Scholar
• Yang J, Zeng XM, Men YL, Zhao LS. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus – a systematic review. Virol. J.5, 100 (2008).
   PubMed Web of Science ®Google Scholar
• Zou H, Chen Y, Duan Z, Zhang H, Pan C. Abstract 235: A retrospective study for clinical outcome of caesarean section on perinatal transmission of Hepatitis B virus in infants born to HBeAg positive mothers with chronic hepatitis B (CHB). Hepatology52(S1), 422A–522A (2010).
   Google Scholar
• Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet. Gynecol.116(1), 147–159 (2010).
   PubMed Web of Science ®Google Scholar
• Bond WW, Petersen NJ, Favero MS. Viral hepatitis B: aspects of environmental control. Health Lab. Sci.14(4), 235–252 (1977).
   PubMedGoogle Scholar
• MacCannell T, Laramie AK, Gomaa A, Perz JF. Occupational exposure of health care personnel to hepatitis B and hepatitis C: prevention and surveillance strategies. Clin. Liver Dis.14(1), 23–36, VII (2010).
   PubMedGoogle Scholar
• Shikata T, Karasawa T, Abe K et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J. Infect. Dis.136(4), 571–576 (1977).
   PubMed Web of Science ®Google Scholar
• U.S. Public Health Service. Updated U.S. Public Health Service Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm. Rep.50(RR-11), 1–52 (2001).
   PubMedGoogle Scholar
• Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. Lancet1(8219), 550–551 (1981).
   PubMed Web of Science ®Google Scholar
• Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis – United States, 2007. MMWR Surveill. Summ.58(3), 1–27 (2009).
   PubMedGoogle Scholar
• Kennedy M, Alexopoulos SP. Hepatitis B virus infection and liver transplantation. Curr. Opin. Organ. Transplant.15(3), 310–315 (2010).
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am. J. Gastroenterol.101(6), 1370–1378 (2006).
   PubMedGoogle Scholar
• Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl.11(7), 716–732 (2005).
   PubMed Web of Science ®Google Scholar
• McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation61(9), 1358–1364 (1996).
   PubMed Web of Science ®Google Scholar
• Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology24(6), 1327–1333 (1996).
   PubMed Web of Science ®Google Scholar
• Sawyer RG, McGory RW, Gaffey MJ et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann. Surg.227(6), 841–850 (1998).
   PubMed Web of Science ®Google Scholar
• Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J. Viral Hepat.14(Suppl. 1), 37–44 (2007).
   PubMedGoogle Scholar
• Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int.29(9), 1294–1305 (2009).
   PubMed Web of Science ®Google Scholar
• Golling M, Arnold JC, Rudek B et al. HBV prophylaxis: cost/benefit analysis following liver transplantation for HBV-positive liver cirrhosis. Transplant. Proc.30(7), 3316–3317 (1998).
   PubMedGoogle Scholar
• So SK, Esquivel CO, Imperial JC, Garcia G, Monge H, Keeffe EB. Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis? J. Gastroenterol. Hepatol.14(Suppl.), S48–S52 (1999).
   Google Scholar
• Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet337(8745), 813–815 (1991).
   PubMed Web of Science ®Google Scholar
• Lemmens HP, Langrehr JM, Blumhardt G et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. Transplant. Proc.26(6), 3622–3623 (1994).
   PubMedGoogle Scholar
• Konig V, Hopf U, Neuhaus P et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation58(5), 553–559 (1994).
   PubMed Web of Science ®Google Scholar
• Targhetta S, Villamil F, Inturri P et al. Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. World J. Gastroenterol.12(11), 1706–1712 (2006).
   PubMed Web of Science ®Google Scholar
• Gugenheim J, Baldini E, Ouzan D, Mouiel J. Absence of initial viral replication and long-term high dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation. Transplant. Proc.29(1–2), 517–518 (1997).
   PubMedGoogle Scholar
• Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology33(2), 424–432 (2001).
   PubMed Web of Science ®Google Scholar
• Xia J, Wang YG, Wang YM. Efficacy of lamivudine for prevention of hepatitis B virus reinfection after liver transplantation. Chin. J. Organ Transplant.27, 167–169 (2006).
   Google Scholar
• Han SH, Ofman J, Holt C et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl.6(6), 741–748 (2000).
   PubMed Web of Science ®Google Scholar
• Honaker MR, Shokouh-Amiri MH, Vera SR et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl. Infect. Dis.4(3), 137–143 (2002).
   PubMedGoogle Scholar
• Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology28(2), 585–589 (1998).
   PubMed Web of Science ®Google Scholar
• Sousa JM, Pareja F, Serrano J et al. Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. Transplant. Proc.35(2), 723–724 (2003).
   PubMedGoogle Scholar
• Neff GW, O’Brien CB, Nery J et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl.10(11), 1372–1378 (2004).
   PubMedGoogle Scholar
• Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given “on demand” in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation77(8), 1203–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Anselmo DM, Ghobrial RM, Jung LC et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann. Surg.235(5), 611–619; discussion 619–620 (2002).
   PubMed Web of Science ®Google Scholar
• Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology132(3), 931–937 (2007).
   PubMed Web of Science ®Google Scholar
• Karademir S, Astarcioglu H, Akarsu M et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant. Proc.38(2), 579–583 (2006).
   PubMedGoogle Scholar
• Zheng S, Chen Y, Liang T et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl.12(2), 253–258 (2006).
   PubMed Web of Science ®Google Scholar
• Buti M, Mas A, Prieto M et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J. Hepatol.38(6), 811–817 (2003).
   PubMed Web of Science ®Google Scholar
• Neff GW, Kemmer N, Kaiser TE et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig. Dis. Sci.52(10), 2497–2500 (2007).
   PubMed Web of Science ®Google Scholar
• Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology48(5), 1460–1466 (2008).
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Papatheodoridis GV, Goulis I, Akriviadis E. Abstract 1151. Combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogue(s) [NUC(s)] for prophylaxis against post-transplant HBV recurrence: a systematic review. Hepatology52(S1), 422A–522A (2010).
   Google Scholar
• Teperman L, Spivey J, Poordad F et al. 28 emtricitabine/tenofovir DF combination +/- HBIG post-orthotopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment: interim results. J. Hepatol.52(Suppl. 1), S12–S13 (2010).
   Google Scholar
• Chen J, Yi L, Jia JD, Ma H, You H. Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: a systematic review. J. Gastroenterol. Hepatol.25(5), 872–879 (2010).
   PubMed Web of Science ®Google Scholar
• Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl. Infect. Dis.12(4), 292–308 (2010).
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology50(3), 661–662 (2009).
   PubMed Web of Science ®Google Scholar
• Marzano A, Marengo A, Andreone P et al. Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. Minerva Med.101(6), 373–383 (2010).
   PubMed Web of Science ®Google Scholar
• Degertekin B, Han SH, Keeffe EB et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am. J. Transplant.10(8), 1823–1833 (2010).
   PubMedGoogle Scholar
• Singham J, Greanya ED, Lau K, Erb SR, Partovi N, Yoshida EM. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann. Hepatol.9(2), 166–171 (2010).
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J. Hepatol.52(2), 272–279 (2010).
   PubMed Web of Science ®Google Scholar
• Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl.16(3), 300–307 (2010).
   PubMedGoogle Scholar
• Vizzini G, Gruttadauria S, Volpes R et al. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts. Clin. Transplant.25(1), E77–E81 (2011).
   PubMedGoogle Scholar
• Brock GN, Mostajabi F, Ferguson N et al. Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Transpl. Int.24(6), 570–581 (2011).
   PubMed Web of Science ®Google Scholar
• Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA. Hepatitis B virus (HBV) quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl. DOI: 10.1002/lt.22312 (2011) (Epub ahead of print).
   PubMedGoogle Scholar